6827 Stock Overview
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MegaPro Biomedical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$23.40 |
| 52 Week High | NT$35.10 |
| 52 Week Low | NT$20.40 |
| Beta | 0 |
| 1 Month Change | -14.29% |
| 3 Month Change | -0.64% |
| 1 Year Change | -12.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6827 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -4.5% | 3.2% | 1.1% |
| 1Y | -12.4% | -24.1% | 28.2% |
Return vs Industry: 6827 exceeded the TW Biotechs industry which returned -24.1% over the past year.
Return vs Market: 6827 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
| 6827 volatility | |
|---|---|
| 6827 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6827 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6827's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Jassy Wang | www.megaprobio.com |
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.
MegaPro Biomedical Co., Ltd Fundamentals Summary
| 6827 fundamental statistics | |
|---|---|
| Market cap | NT$1.52b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6827 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6827 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6827 perform over the long term?
See historical performance and comparison